公开(公告)号：CA2969709A1

公开(公告)日：2016-06-09

申请号：CA2969709

申请日：2015-12-04

Applicant: ARRAY BIOPHARMA INC ,  CELGENE CORP

Inventor： ALLEN SHELLEY ,  BOYS MARK LAURENCE ,  CHICARELLI MARK J ,  FELL JAY BRADFORD ,  FISCHER JOHN P ,  GAUDINO JOHN ,  HICKEN ERIK JAMES ,  HINKLIN RONALD JAY ,  KRASER CHRISTOPHER F ,  LAIRD ELLEN ,  ROBINSON JOHN E ,  TANG TONY P ,  BURGESS LAURENCE E ,  RIEGER ROBERT ANDREW ,  PHENEGER JED ,  SATOH YOSHITAKA ,  LEFTHERIS KATERINA ,  RAHEJA RAJ K ,  BENNETT BRYDON L

IPC: C07D487/04 ,  A61K31/4985 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06

Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

公开(公告)号：AU2011240808B2

公开(公告)日：2015-01-22

申请号：AU2011240808

申请日：2011-04-11

Applicant: ARRAY BIOPHARMA INC

Inventor： BOYS MARK LAURENCE ,  BURGESS LAURENCE E ,  GRONEBERG ROBERT D ,  HARVEY DARREN M ,  HUANG LILY ,  KERCHER TIMOTHY ,  KRASER CHRISTOPHER F ,  LAIRD ELLEN ,  TARLTON EUGENE ,  ZHAO QIAN

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P37/00

Abstract: Compounds of Formula I: (Formula should be inserted here) and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R

公开(公告)号：CR20120572A

公开(公告)日：2013-02-20

申请号：CR20120572

申请日：2012-11-09

Applicant: ARRAY BIOPHARMA INC

Inventor： BOYS MARK LAURENCE ,  BURGESS LAURENCE E ,  GRONEBERG ROBERT D ,  HARVEY DARREN M ,  HUANG LILY ,  KERCHER TIMOTHY ,  KRASER CHRISTOPHER F ,  LAIRD ELLEN ,  TARLTON EUGENE ,  ZHAO QIAN

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P37/00

Abstract: Los compuestos de la Fórmula I y estereoisómeros y sales y solvatos de los mismos farmacéuticamente aceptables en los cuales R1, R2, R3, R4, R5, R6, R7, X1 y X2 tienen los significados dados en la especificación, son inhibidores de una o más cinasas JAK y son útiles en el tratamiento de enfermedades autoinmunitarias, enfermedades inflamatorias, rechazo de órganos, tejidos y células transplantados, así como también trastornos hematológicos y malignidades y sus co-morbilidades.

公开(公告)号：RS52298B

公开(公告)日：2012-12-31

申请号：RSP20120119

申请日：2007-01-26

Applicant: ARRAY BIOPHARMA INC

Inventor： LAIRD ELLEN ,  GRONEBERG ROBERT ,  BURGESS LAURENCE E ,  HARVEY DARREN ,  MUNSON MARK ,  RIZZI JAMES ,  EARY CHARLES TODD ,  WATSON DANIEL ,  RODRIGUEZ MARTHA

IPC: C07D231/40 ,  A61K31/416 ,  A61P29/00 ,  C07D231/56

Abstract: The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.

公开(公告)号：SG184870A1

公开(公告)日：2012-11-29

申请号：SG2012076493

申请日：2011-04-11

Applicant: ARRAY BIOPHARMA INC

Inventor： BOYS MARK LAURENCE ,  BURGESS LAURENCE E ,  GRONEBERG ROBERT D ,  HARVEY DARREN M ,  HUANG LILY ,  KERCHER TIMOTHY ,  KRASER CHRISTOPHER F ,  LAIRD ELLEN ,  TARLTON EUGENE ,  ZHAO QIAN

Abstract: Compounds of Formula I: (Formula should be inserted here) and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, R7, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

公开(公告)号：SG178899A1

公开(公告)日：2012-04-27

申请号：SG2012013751

申请日：2010-08-27

Applicant: ARRAY BIOPHARMA INC ,  GENENTECH INC

Inventor： ALIAGAS IGNACIO ,  GRADL STEFAN ,  GUNZNER JANET ,  LEE WENDY ,  MATHIEU SIMON ,  RUDOLPH JOACHIM ,  WEN ZHAOYANG ,  ZHAO GUILING ,  BUCKMELTER ALEXANDRE J ,  GRINA JONAS ,  HANSEN JOSHUA D ,  LAIRD ELLEN ,  MORENO DAVID ,  REN LI ,  WENGLOWSKY STEVEN MARK

Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：AT542800T

公开(公告)日：2012-02-15

申请号：AT07762713

申请日：2007-01-26

Applicant: ARRAY BIOPHARMA INC

Inventor： GRONEBERG ROBERT ,  BURGESS LAURENCE ,  HARVEY DARREN ,  LAIRD ELLEN ,  MUNSON MARK ,  RIZZI JAMES ,  RODRIGUEZ MARTHA ,  EARY CHARLES ,  WATSON DANIEL

IPC: C07D231/40 ,  A61K31/416 ,  A61P29/00 ,  C07D231/56

Abstract: The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.

公开(公告)号：CA2796388A1

公开(公告)日：2011-10-20

申请号：CA2796388

申请日：2011-04-11

Applicant: ARRAY BIOPHARMA INC

Inventor： BOYS MARK LAURENCE ,  BURGESS LAURENCE E ,  GRONEBERG ROBERT D ,  HARVEY DARREN M ,  HUANG LILY ,  KERCHER TIMOTHY ,  KRASER CHRISTOPHER F ,  LAIRD ELLEN ,  TARLTON EUGENE ,  ZHAO QIAN

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P37/00

Abstract: Compounds of Formula I: (Formula should be inserted here) and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, R7, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

公开(公告)号：CA2772316A1

公开(公告)日：2011-03-03

申请号：CA2772316

申请日：2010-08-27

Applicant: ARRAY BIOPHARMA INC ,  GENENTECH INC

Inventor： GRADL STEFAN ,  LAIRD ELLEN ,  MORENO DAVID ,  REN LI ,  WENGLOWSKY STEVEN MARK

IPC: C07D471/04 ,  A61K31/437 ,  A61P13/12 ,  A61P35/00

Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. [FORMULA I]

公开(公告)号：CA2772074A1

公开(公告)日：2011-03-03

申请号：CA2772074

申请日：2010-08-27

Applicant: ARRAY BIOPHARMA INC ,  GENENTECH INC

Inventor： ALIAGAS IGNACIO ,  GRADL STEFAN ,  GUNZNER JANET ,  MATHIEU SIMON ,  PULK REBECCA ,  RUDOLPH JOACHIM ,  WEN ZHAOYANG ,  GRINA JONAS ,  HANSEN JOSHUA D ,  LAIRD ELLEN ,  MORENO DAVID ,  REN LI ,  WENGLOWSKY STEVEN MARK

IPC: C07D487/04 ,  A61K31/38 ,  A61P35/00 ,  C07D495/04 ,  C07D513/04

Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.